CN102702014A - Method for preparing atorvastatin calcium intermediate - Google Patents

Method for preparing atorvastatin calcium intermediate Download PDF

Info

Publication number
CN102702014A
CN102702014A CN2012101680677A CN201210168067A CN102702014A CN 102702014 A CN102702014 A CN 102702014A CN 2012101680677 A CN2012101680677 A CN 2012101680677A CN 201210168067 A CN201210168067 A CN 201210168067A CN 102702014 A CN102702014 A CN 102702014A
Authority
CN
China
Prior art keywords
reaction
atorvastatincalcuim
solvent
intermediates preparation
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012101680677A
Other languages
Chinese (zh)
Other versions
CN102702014B (en
Inventor
胡玉玺
路显峰
冯建鹏
程瑞玲
张薇
居斌
胡丽娜
陆良喆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Haici Biological Pharmaceutical Co Ltd Of Yangtze River Pharmaceutical Group
Original Assignee
Jiangsu Haici Biological Pharmaceutical Co Ltd Of Yangtze River Pharmaceutical Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Haici Biological Pharmaceutical Co Ltd Of Yangtze River Pharmaceutical Group filed Critical Jiangsu Haici Biological Pharmaceutical Co Ltd Of Yangtze River Pharmaceutical Group
Priority to CN201210168067.7A priority Critical patent/CN102702014B/en
Publication of CN102702014A publication Critical patent/CN102702014A/en
Application granted granted Critical
Publication of CN102702014B publication Critical patent/CN102702014B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

The invention provides a method for preparing atorvastatin calcium intermediate. The method comprises the steps of dissolving compound A and compound B into a solvent with a molar ratio of A to B of 1:(1.0-1.5), heating to 30-60 DEG C, stirring to dissolve, slowly dripping concentrated acid with a mole number of 2-8 times of that of compound A for a reaction for 16-36 hours at 80-110 DEG C, removing water formed during the reaction by using a water separator after the reaction, removing the solvent through rotary dying, dissolving with ethyl acetate, adding petroleum ether dropwise for recrystallization and treating for several times to obtain the final product. The two raw materials A and B used in the method are cheap and available, the catalyst of the reaction is common acid, and the product of the side reaction is only water. The obtained product has a purity of over 98% and a yield of about 80% and accords with the requirements of friendly environment and green chemistry.

Description

A kind of atorvastatincalcuim intermediates preparation
Technical field
The present invention relates to a kind of atorvastatincalcuim intermediates preparation, belong to medical production technical field.
Background technology
(Lipitor was the maximum anticholesteremic agent of present global recipe quantity Lipitor) to atorvastatin, became the whole world prescription drugs that is in great demand most from 2002, and annual sales amount reaches 10,000,000,000 dollars.Five patents about Lipitor all will expire in the recent period successively.Wherein the related Lipitor calcium salt patent (US 5273995) of this problem will expire in June, 2011.At present, to the end of the year 2010, the Lipitor of auspicious brightness company occupies Chinese market annual turnover 69.18%, and annual sales amount reaches several hundred million yuans.In addition, domestic preparation mainly contains the atorvastatin calcium tablet (trade(brand)name: A Le) cut down his spit of fland calcium capsule (trade(brand)name: You Jia) with the holder of Henan old name for the Arabian countries in the Middle East medicine company that the good woods medicine company in Beijing is rushed to register on the market.
The main method of at present synthetic atorvastatincalcuim is two segmental linked reactions (as follows), and wherein AT-9 mainly contains following two kinds of synthetic routes:
Figure 2012101680677100002DEST_PATH_RE-DEST_PATH_IMAGE002
Article one, be 1992 by people such as Butler, be committed step with the Stetter reaction, make aldehyde under catalyst action, carry out 1,4 addition with alpha, beta-unsaturated ketone, generate 1, the 4-diketone.The advantage of this route is that step is fairly simple, is suitable for industrialized production, and main drawback is: 1) price comparison of key intermediate p-Fluorobenzenecarboxaldehyde is expensive; 2) selection of Stetter catalysts has a lot, finds that finally effective catalyzer is one type of thiazoles carbone catalyst, and this type catalyzer is not easy to obtain, and cost is high again, but also the foul smelling flavor, environment is unfriendly.
Figure DEST_PATH_RE-DEST_PATH_IMAGE003
  
Second type of route then is to be raw material with the phenyllacetyl chloride, through Friedel-Crafts reaction and bromo-reaction Synthetic 2-bromo-1-(4-fluorophenyl)-methyl phenyl ketone, subsequently bromine carried out substitution reaction and obtains Segment A.Compare with article one route, its advantage is: 1) respectively go on foot reagent and cheaply be easy to get, be beneficial to and reduce cost; 2) reaction conditions is also relatively gentleer, and by product is less; 3) overall yield is higher.But still have some shortcomings, mainly contain: 1) reactions step is longer; 2) reaction earlier will be on the carbonyl alpha-position bromine, final step removes bromine when replacing again, Atom economy is relatively poor; 3) though the use expensive catalysts has been avoided in reaction, the liquid bromine that uses still has pungency and corrodibility, still need improve aspect waste pollution processing and the environment protection.
Figure 2012101680677100002DEST_PATH_RE-DEST_PATH_IMAGE004
Summary of the invention
The objective of the invention is to overcome the weak point of prior art, a kind of atorvastatincalcuim intermediates preparation is provided.
Atorvastatincalcuim intermediates preparation of the present invention; Comprise the steps: compd A and compd B are dissolved in the solvent; Wherein the molar ratio of A and B is 1: (1.0-1.5), be heated to temperature 30-60 ℃, stirring and dissolving; Slowly drip concentrated acid, the mole number of concentrated acid is 2-8 a times of compd A; 80-110 ℃ of down reaction 16-36 hour, utilize water trap to remove the water that dereaction generates after reaction finishes, revolve dried solvent, use acetic acid ethyl dissolution, dropping sherwood oil recrystallization, repeated treatments repeatedly,
Concrete reaction formula is following:
Figure DEST_PATH_DEST_PATH_IMAGE006
Described solvent is DMSO, ETHYLE ACETATE or toluene;
Described concentrated acid is the vitriol oil, phosphoric acid or polyphosphoric acid;
The molar ratio of described A and B is 1: (1.1-1.3);
Described temperature of reaction is 90-100 ℃;
The described reaction times is 24-28 hour.
Used two raw material A of the present invention and B is relatively inexpensive is easy to get, this reaction catalyst system therefor is a customary acid, side reaction is merely water.Products therefrom purity is greater than 98%, and yield about 80% meets the requirement of environmental friendliness and Green Chemistry.
Embodiment
Combine embodiment at present, the present invention is done further elaboration.
Embodiment 1
In compd A (2.3g) and compd B (2.7g) dissolving and 50ml exsiccant toluene solvant, be heated to 45 ℃, stir 30min, slowly drip the 3.5g vitriol oil, dropwise, continue stirring 30min, be warming up to 90 ℃, fraction water device water-dividing.To react 24 hours. reaction is washed with water to neutrality after finishing, saturated solution of sodium bicarbonate washing organic phase.Anhydrous sodium sulfate drying. after removing solvent under reduced pressure, use the 50ml acetic acid ethyl dissolution, mechanical stirring.Be heated to 30 ℃, slowly drip sherwood oil 150ml, get product. repeat above-mentioned re-crystallization step 2 times, get product 3.2g.
Embodiment 2
Compd A (30g) and compd B (35g) are dissolved in the 300ml dry toluene solvent, are heated to 45 ℃, stir 30min, slowly Dropwise 5 0g SPA dropwises, and continues to stir 30min, is warming up to 90 ℃, fraction water device water-dividing.To react 26 hours. reaction is washed with water to neutrality after finishing, saturated solution of sodium bicarbonate washing organic phase.Anhydrous sodium sulfate drying. after removing solvent under reduced pressure, use the 200ml acetic acid ethyl dissolution, mechanical stirring. be heated to 30 ℃, slowly drip sherwood oil 600ml, get product. repeat above-mentioned re-crystallization step 2 times, get product 44.8g.
Embodiment 3
Compd A (100g) and compd B (115g) are dissolved in the 1000ml dry toluene solvent, are heated to 45 ℃, stir 30min, slowly drip the 160g SPA, dropwise, continue to stir 30min, be warming up to 90 ℃, fraction water device water-dividing. reacted 26 hours.Reaction is washed with water to neutrality after finishing, saturated solution of sodium bicarbonate washing organic phase.Anhydrous sodium sulfate drying.After removing solvent under reduced pressure, use the 1000ml acetic acid ethyl dissolution, mechanical stirring.Be heated to 30 ℃, slowly drip sherwood oil 3000ml, get product. repeat above-mentioned re-crystallization step 2 times, get product 151.0g.
  

Claims (6)

1. atorvastatincalcuim intermediates preparation; It is characterized in that comprise the steps: compd A and compd B are dissolved in the solvent, wherein the molar ratio of A and B is 1: (1.0-1.5); Be heated to temperature 30-60 ℃; Stirring and dissolving slowly drips concentrated acid, and the mole number of concentrated acid is 2-8 a times of compd A; 80-110 ℃ of down reaction 16-36 hour, utilize water trap to remove the water that dereaction generates after reaction finishes, revolve dried solvent, use acetic acid ethyl dissolution, dropping sherwood oil recrystallization, repeated treatments repeatedly,
Concrete reaction formula is following:
Figure 431220DEST_PATH_IMAGE001
2. atorvastatincalcuim intermediates preparation according to claim 1 is characterized in that, described solvent is DMSO, ETHYLE ACETATE or toluene.
3. atorvastatincalcuim intermediates preparation according to claim 1 is characterized in that, described concentrated acid is the vitriol oil, phosphoric acid or polyphosphoric acid.
4. atorvastatincalcuim intermediates preparation according to claim 1 is characterized in that, the molar ratio of described A and B is 1: (1.1-1.3).
5. atorvastatincalcuim intermediates preparation according to claim 1 is characterized in that, described temperature of reaction is 90-100 ℃.
6. atorvastatincalcuim intermediates preparation according to claim 1 is characterized in that, the described reaction times is 24-28 hour.
CN201210168067.7A 2012-05-28 2012-05-28 Method for preparing atorvastatin calcium intermediate Active CN102702014B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210168067.7A CN102702014B (en) 2012-05-28 2012-05-28 Method for preparing atorvastatin calcium intermediate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210168067.7A CN102702014B (en) 2012-05-28 2012-05-28 Method for preparing atorvastatin calcium intermediate

Publications (2)

Publication Number Publication Date
CN102702014A true CN102702014A (en) 2012-10-03
CN102702014B CN102702014B (en) 2014-03-19

Family

ID=46895137

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210168067.7A Active CN102702014B (en) 2012-05-28 2012-05-28 Method for preparing atorvastatin calcium intermediate

Country Status (1)

Country Link
CN (1) CN102702014B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103614430A (en) * 2013-11-22 2014-03-05 苏州卫生职业技术学院 Synthetic method of atorvastatin calcium intermediate
CN114195670A (en) * 2021-12-31 2022-03-18 河南豫辰药业股份有限公司 Refining method of atorvastatin mother nucleus M4
CN115260051A (en) * 2022-08-26 2022-11-01 江苏阿尔法药业股份有限公司 Preparation process of atorvastatin calcium intermediate
CN115466196A (en) * 2022-08-30 2022-12-13 宿迁阿尔法科技有限公司 Preparation method of atorvastatin calcium intermediate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101307009A (en) * 2007-05-15 2008-11-19 浙江京新药业股份有限公司 New synthetic method for (earth)4-fluor-alpha-(2-methyl-1-oxypropyl )-gamma-oxo-N, beta-diphenyl benzene butanamide
WO2009084827A2 (en) * 2007-12-27 2009-07-09 Dong-A Pharm.Co., Ltd. Synthetic intermediates, process for preparing pyrrolylheptanoic acid derivatives therefrom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101307009A (en) * 2007-05-15 2008-11-19 浙江京新药业股份有限公司 New synthetic method for (earth)4-fluor-alpha-(2-methyl-1-oxypropyl )-gamma-oxo-N, beta-diphenyl benzene butanamide
WO2009084827A2 (en) * 2007-12-27 2009-07-09 Dong-A Pharm.Co., Ltd. Synthetic intermediates, process for preparing pyrrolylheptanoic acid derivatives therefrom

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103614430A (en) * 2013-11-22 2014-03-05 苏州卫生职业技术学院 Synthetic method of atorvastatin calcium intermediate
CN114195670A (en) * 2021-12-31 2022-03-18 河南豫辰药业股份有限公司 Refining method of atorvastatin mother nucleus M4
CN114195670B (en) * 2021-12-31 2024-03-15 河南豫辰药业股份有限公司 Refining method of atorvastatin mother nucleus M4
CN115260051A (en) * 2022-08-26 2022-11-01 江苏阿尔法药业股份有限公司 Preparation process of atorvastatin calcium intermediate
CN115466196A (en) * 2022-08-30 2022-12-13 宿迁阿尔法科技有限公司 Preparation method of atorvastatin calcium intermediate
CN115466196B (en) * 2022-08-30 2024-03-26 宿迁阿尔法科技有限公司 Preparation method of atorvastatin calcium intermediate

Also Published As

Publication number Publication date
CN102702014B (en) 2014-03-19

Similar Documents

Publication Publication Date Title
CN102702014A (en) Method for preparing atorvastatin calcium intermediate
CN103739500B (en) A kind of synthesis of cinacalcet hydrochloride and process for purification
CN102381970B (en) Method for preparing flurbiprofen axetil compound
CN109180625A (en) A kind of preparation method of seleno flavone compound
CN104945341B (en) A kind of method of the triazole compound of three components one pot process 1,2,3
Renteria-Gomez et al. Regiospecific synthesis of 1-acetamide-5-methoxy-2-oxindoles in two steps:(Ugi-SN2)/xanthate mediated free radical cyclization
CN105152947A (en) Preparation method of 2-amino-3,5-dibromobenzaldehyde
Cui et al. 2, 3, 10, 11‐Tetrahydroxytetraphenylene and Its Application in Molecular Recognition
CN102417472B (en) Preparation method of florfenicol
CN103351283A (en) Preparation method of parachlorometaxylenol
CN102731333A (en) Method for preparing tetracaine
CN105367470A (en) Method for preparing vildagliptin
CN102267911A (en) Synthesis method of methyl salicylate
CN104447678A (en) Method for preparing Invokana key intermediate
CN108752218B (en) Route for preparing dolutegravir key intermediate 2, 4-difluorobenzylamine
CN102199154B (en) Novel synthesis method for pyrrole derivatives
CN105085267A (en) Synthetic method for salvianolic acid A
CN104529726B (en) A kind of preparation method of o-hydroxyacetophenone
CN102381995A (en) Preparation method of metoprolol
CN113024364A (en) Efficient green synthesis method of hydroxycitronellal
CN101337955B (en) Method for preparing high optical purity 3-substituted chiral phthalide compounds
CN103570546B (en) A kind of Industrialized synthesis method of danshensu norbornene ester
CN108329218A (en) It is a kind of(R)Adrenergic preparation method
CN103980225A (en) Synthetic method of beta-amino acid with thiazole ring connected to nitrogen
CN102898289B (en) Method for synthesizing 2-(4-benzylmethoxyphenyl)ethanol medical intermediate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant